Induction of antibody responses in the common mucosal immune system by respiratory syncytical virus immunostimulating complexes

Medical Microbiology and Immunology

Volumn 187, Issue 4, 1999, Pages 191-198

  Hu, Ke Fei ^a   Ekström, Jill ^b   Merza, Malik ^b   Lövgren Bengtsson, Karin ^a   Morein, Bror ^a,b  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^b NATIONAL VETERINARY INSTITUTE   (Sweden)

Author keywords

gp120; IgA; IgG; Immunostimulating complexes; Virus neutralizing antibody

Indexed keywords

ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; GENITAL SYSTEM; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSTIMULATION; INTESTINE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; LUNG; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SUBCUTANEOUS DRUG ADMINISTRATION; UPPER RESPIRATORY TRACT;

EID: 0032912036     PISSN: 03008584     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004300050092     Document Type: Article

References (37)

1. 1. Bergquist C, Lagergård T, Lindblad M, Holmgren J (1995) Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates. Infect Immun 63: 2021-2025
2. 2. Claassen I, Osterhaus A, Boersma W, Schellekens M, Claasen E (1995) Fluorescent labelling of virus, bacteria and iscoms: in vivo systemic and mucosal localisation patterns. Adv Exp Med Biol 371B: 1485-1489
3. 3. Cleland JL (1995) Vaccine design: the subunit and adjuvant approach. Plenum Press, New York, pp 439-462
4. 4. Coombes AGA, Lavells EC, Jenkins PG, Davis SS (1996) Single dose, polymeric, microparticle-based vaccines: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen. Vaccine 14: 1429-1438
5. 5. Czerkinsky C, Holmgren J (1995) The mucosal immune system and prospects for anti-infectious and anti-inflammatory vaccines. Immunologist 3: 97-103
6. 6. Davis D, Morein B, Åkerblom L, Lövgren-Bengtsson K, Gils ME van , Bogers WM, Teeuwsen VJ, Heeney JL (1997) A recombinant prime, peptide boost vaccination strategy can focus the immune response on to more than one epitope even though these may not be immunodominant in the complex immunogen. Vaccine 15: 1661-1669
7. 7. Ekström J, Hu K-F, Lövgren-Bengtsson K, Morein B (1999) ISCOMs and ISCOM matrix enhance by intranasal route the IgA responses to OVA and rCTB in local and remote mucosal secretions. Vaccine (in press)
8. 8. Haan A de , Reneger KB, Small PA Jr, Wilschut J (1995) Induction of a secretory IgA response in the murine female urogenital tract by immunization of the lungs with liposome-supplemented viral subunit antigen. Vaccine 13: 613-616
9. 9. Holmgren J, Czerkinsky C, Lycke N, Svennerholm AM (1994) Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant. Am J Trop Med Hyg 50 [Suppl 5]: 42-54
10. 10. Hordnes K, Tynning T, Brown TA, Haneberg B, Jonsson R (1997) Nasal immunization with group B streptococci can induce high levels of specific IgA antibodies in cervicovaginal secretions of mice. Vaccine 15: 1244-1251
11. 11. Hu K-F, Elvander M, Merza M, Åkerblom L, Branderburg A, Morein B (1998) The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses. Clin Exp Immunol 113: 235-243
12. 12. Hu K-F, Morein B, Merza M (1998) Using distilled water for the extraction of mucosal antibodies and the subsequent application in RSV neutralization test. J Immunoassay 19: 209-222
13. 13. Jones PD, Tha Hla R, Morein B, Lövgren K, Ada GL (1988) Cellular immune responses in the murine lung to local immunization with influenza A virus glycoproteins in micelles and immunostimulating complexes (iscoms). Scand J Immunol 27: 645-652
14. 14. Kimman TG, Westenbrink F, Straver PJ, Van Zaane D, Schreuder BE (1987) Isotype-specific ELISAs for the detection of antibodies to bovine respiratory syncytial virus. Res Vet Sci 43: 180-187
15. 15. Komase K, Tamura S, Matsuo K, Watanabe K, Hattori N, Odaka A, Suzuki Y, Kurata T, Aizawa C (1998) Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine. Vaccine 16: 248-254
16. 16. Lövgren K, Lindmark J, Pipkorn R, Morein B (1987) Antigenic presentation of small molecules and peptides conjugated to a preformed iscom as carrier. J Immunol Methods 98: 137-143
17. 17. Lövgren-Bengtsson K (1998) Preparation and use of adjuvants. In: Kaufmann SHE and Kabelitz D (eds) Immunology of infection. Methods in microbiology, vol 25. Academic Press, San Diego, pp 471-502
18. 18. Morein B, Sharp M, Sundquist B, Simons K (1983) Protein subunit vaccines of parainfluenza type 3 virus: immunogenic effect in lambs and mice. J Gen Virol 4: 1557-1569
19. 19. Morein B, Sundquist B, Dalsgaard K, Osterhaus A (1984) Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308: 457-460
20. 20. Morein B, Lövgren K, Sundquist B (1987) Iscom - an immunostimulating complex. Immunol Today 8: 333-338
21. 21. Morein B, Lövgren K, Rönnberg B, Sjölander A, Villacres-Eriksson M (1995) Immunostimulating complexes, clinical potential in vaccine development. Clin Immunother 3: 461-475
22. 22. Morein B, Villacrés-Eriksson M, Sjölander A, Lövgren-Bengtsson K (1996) Novel adjuvants and vaccine delivery systems. Vet Immunol Immunopathol 54: 373-384
23. 23. Mowat AM, Donachie AM (1991) ISCOMs - a novel strategy for mucosal immunization? Immunol Today 12: 383-385
24. 24. Mowat AM, Maloy KJ (1994) Immune stimulating complexes as vectors for oral immunization. In: O'Hagan DT (ed) Novel delivery systems for oral vaccines. CRC Press, Boca Raton, pp 207-223
25. 25. Murphy BR (1994) Mucosal immunity to viruses. In: Ogra PL, Strober W, Mestecky J, McGhee JR, Lamm ME, Bienestock J (eds) Handbook of mucosal immunology. Academic Press, San Diego, pp 333-343
26. 26. Phillips-Quagliata JM, Lamm ME (1994) Lymphocyte homing to mucosal effector sites. In: Ogra P L, Strober W, Mestecky J, McGhee JR, Lamm ME, Bienestock J (eds) Handbook of mucosal immunology. Academic Press, San Diego, pp 225-239
27. 27. Pierce NF, Cray WC Jr (1981) Cellular dissemination of priming for a mucosal immune response to cholera toxin in rats. J Immunol 127: 2461-2464
28. 28. Rosenthal KL, Gallichan WS (1997) Challenges for vaccination against sexually transmitted diseases: induction and long-term maintenance of mucosal immune responses in the female genital tract. Semin Immunol 9: 303-314
29. 29. Russell MW, Moldoveanu Z, White PL, Sibert GJ, Mestechy J, Michalek SM (1996) Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunit. Infect Immun 64: 1272-1283
30. 30. Smith RE, Donachie AM, Mclaren FH, Mowat AM (1998) Preservation of mucosal and systemic adjuvant properties of ISCOMs in the absence of functional interleukin-4 or interferon-γ. Immunology 93: 556-562
31. 31. Speijers GJA, Danse LHJ, Beuvery EC, Strik JJTWA, Vos JG (1988) Local reactions of the saponin Quil A and a Quil A containing iscom measles vaccine after intramuscular injection of rats: a comparison with the effect of DPT-polio vaccine. Fund Appl Toxicol 10: 425-430
32. + cytotoxic T cells by immunization with purified HIV-1 envelope protein in iscoms. Nature 344: 873-875
33. 33. Trudel M, Nadon F, Seguin C, Simard C, Lussier G (1989) Experimental polyvalent ISCOMs subunit vaccine induces antibodies that neutralize human and bovine respiratory syncytial virus. Vaccine 7: 12-16
34. 34. Trudel M, Nadon F, Seguin C, Brault S, Lusignan Y, Lemieux S (1992) Initiation of cytotoxic T-cell response and protection of Balb/c mice by vaccination with an experimental ISCOMs respiratory syncytial virus subunit vaccine. Vaccine 10: 107-112
35. 35. Wilson AD, Lövgren-Bengtsson K, Villacres-Ericsson M, Morein B, Morgan AJ (1999) The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into ISCOMs primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines. Vaccine (in press)
36. 36. Wu H-Y, Russel MW (1998) Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine 16: 286-292
37. 37. Yamamoto S, Takeda Y, Yamamoto M, Kurazono H, Imaoka K, Yamamoto M, Fujihashi K, Noda M, Kiyono H, McGhee JR (1997) Mutants in the ADP-ribosyltransferase cleft cholera toxin lack diarrheagenicity but retain adjuvanticity. J Exp Med 185: 1203-1210